A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.
Survey responses confirm that CSR defunding would have a significant impact on 2018 rates and payers’ continued participation in the ACA exchanges.
A detailed look at what is driving 2018 premium rate increases.
With repeal and replace on pause, the reform spotlight is shifting to 1332 waivers, which give states the ability to waive some provisions of the ACA. A detailed look at the waiver process, state interest, and how health insurers might be impacted.
A look inside our policy brief urging legislators to consider the impact of health reform on US employers and the 177 million people who receive health coverage from them.
A side-by-side comparison of the leading repeal-and-replace proposals.
Despite changing political winds, value-based initiatives are as relevant as ever. Read new analysis of the ACO market and insight into next, best moves.
What does a Trump presidency mean for healthcare organizations? Must-read articles from Oliver Wyman Health.